Search alternatives:
larger decrease » marked decrease (Expand Search)
point decrease » point increase (Expand Search)
large decrease » marked decrease (Expand Search), large increases (Expand Search), large degree (Expand Search)
Showing 21 - 40 results of 6,733 for search '(( using ((mean decrease) OR (point decrease)) ) OR ( a ((large decrease) OR (larger decrease)) ))', query time: 0.73s Refine Results
  1. 21
    Large state-wide variation (8.5-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2019 <sup>a</sup> indicates ≥1.50 SD (16.8) from the mean (31.0), which is denoted by the dotted line. <sup>b</sup> indicates ≥1.96 SD from the mean.

    Large state-wide variation (8.5-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2019 <sup>a</sup> indicates ≥1.50 SD (16.8) from the mean (31.0... by Luke R. Cavanah (19022435)

    Published 2025
    Save to List
    Saved in:
  2. 22
    Large state-wide variation (8.6-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2020 <sup>a</sup> indicates ≥1.50 SD (16.0) from the mean (29.9), which is denoted by the dotted line. <sup>b</sup> indicates ≥1.96 SD from the mean.

    Large state-wide variation (8.6-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2020 <sup>a</sup> indicates ≥1.50 SD (16.0) from the mean (29.9... by Luke R. Cavanah (19022435)

    Published 2025
    Save to List
    Saved in:
  3. 23
    Large state-wide variation (10.2-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2016 <sup>a</sup> indicates ≥1.50 SD (19.2) from the mean (34.8), which is denoted by the dotted line. <sup>b</sup> indicates ≥1.96 SD from the mean.

    Large state-wide variation (10.2-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2016 <sup>a</sup> indicates ≥1.50 SD (19.2) from the mean (34.... by Luke R. Cavanah (19022435)

    Published 2025
    Save to List
    Saved in:
  4. 24
    CM-DWM-EC chart using 30% decrease in the mean for the E(KeV).

    CM-DWM-EC chart using 30% decrease in the mean for the E(KeV). by Shumaila Nisar (20114256)

    Published 2024
    “…<p>CM-DWM-EC chart using 30% decrease in the mean for the E(KeV).</p>…”
    Save to List
    Saved in:
  5. 25
    Summary of post-treatment disease course measures from MDMA-AT publications.

    Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 26
    Study selection criteria.

    Study selection criteria. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 27
    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.

    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 28
    Disease course measures after the PTSD treatments.

    Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 29
    PICOS criteria for the SLR.

    PICOS criteria for the SLR. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 30
    Summary of post-treatment CAPS score changes from MDMA-AT publications.

    Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 31
    Summary of post-treatment disease course measures from off-label medications clinical trials.

    Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 32
    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.

    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 33
    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.

    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 34
    Summary of post-treatment disease course measures from clinical trials with psychotherapies.

    Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 35
    PRISMA flow chart.

    PRISMA flow chart. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 36
    Summary of clinical efficacy of relevant PTSD treatments.

    Summary of clinical efficacy of relevant PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 37
    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.

    Post-treatment CAPS score changes from clinical trials with off-label PTSD medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 38
    Nightlight densities in the lowest, around the median and the highest ranked cities in the sample and the distribution of firms in each city.

    Nightlight densities in the lowest, around the median and the highest ranked cities in the sample and the distribution of firms in each city. by Saul Estrin (8629173)

    Published 2024
    Save to List
    Saved in:
  19. 39
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:
  20. 40
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Save to List
    Saved in:

Search Tools: